Table 1 Descriptive characteristics of the sample
Characteristics | One-year follow-up group (n = 58)a M (SD) or % | Lost group (n = 43) M (SD) or N % | Baseline comparison between the lost group and patients who completed the study t (p) or χ2 (p) | |
|---|---|---|---|---|
Women | 54 (93.1%) | 12 (27.9%) | 8.18 (.004) | |
Age | 71.77 (5.53) | 75.06 (6.32) | −2.8 (.006) | |
Primary cancer site | Breast | 31 (53.4%) | 16 (37.2%) | 7.55 (.056) |
Gynecology | 16 (27.6%) | 9 (21%) | ||
Lung | 8 (13.8%) | 16 (37.2%) | ||
Hematology | 3 (5.2%) | 2 (4.6%) | ||
Cancer staging | Non-metastatic | 53 (91.4%) | 28 (65.1%) | 10.72 (.001) |
Metastatic | 5 (8.6%) | 15 (34.9%) | ||
Kind of cancer | Initial cancer | 48 (82.8%) | 40 (93%) | 2.32 (.12) |
Recurrence or progressive | 10 (17.2%) | 3 (7%) | ||
Charlson Comorbidity Index | 1.79 (1.33) | 2.56 (2.14) | −2.2 (.03) | |
Cognitive functioning | 27.84 (1.96) | 26.83 (2.32) | 2.35 (.02) | |
Global health | Baseline | 79.68 (15.97) | 73.8 (17.38) | 1.75 (.08) |
After 3 months | 75.26 (15.17) | |||
After 6 months | 76.66 (17.53) | |||
After one year | 80.36 (14.2) | |||
Mental health | Baseline | 82.35 (17.7) | 78.68 (19.72) | .956 (.34) |
After 3 months | 79.66 (19.98) | |||
After 6 months | 82.17 (18.97) | |||
After one year | 83.24 (18.5) | |||
Physical health | Baseline | 78.89 (17.46) | 72.33 (18.43) | 1.81 (.073) |
After 3 months | 73.41 (16.9) | |||
After 6 months | 74.98 (18.28) | |||
After one year | 79.5 (15.04) | |||
SPA | Baseline | 87.52 (12.79) | 81.56 (13.36) | 2.19 (.03) |
After 3 months | 84.5 (12.64) | |||
After 6 months | 86.05 (13) | |||
After one year | 84.4 (14.26) | |||
Cancer view | Baseline | 83.31 (9.55) | 80.05 (11.17) | 1.36 (.17) |
After 3 months | 81.1 (10.89) | |||
After 6 months | 84.53 (10.38) | |||
After one year | 84.5 (12.04) | |||